Jun 09, 2021 / 12:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone. Thank you for joining us for Day 2 of the Goldman Sachs Healthcare Conference. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to be joined by Moderna. With us, we have Stephane Bancel, CEO of the company.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPWith that, Stephane, thank you so much for joining us. And to start here, a question on your modalities. You have established 2 modalities or 2 verticals out of the 6 right now, prophylactic vaccines, systemic secreted and cell surface therapeutics as core. And can you remind us what this means and speak to the biological and technology risks that remain in all your exploratory modalities, and the steps needed to derisk these verticals on the forward.
Stephane Bancel - Moderna, Inc. - CEO & Director
Great. Good morning, Salveen, and thank you for the invitation. So maybe let me